Climber Capital SA Has $366,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Climber Capital SA raised its holdings in Johnson & Johnson (NYSE:JNJ) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 2,206 shares of the company’s stock after acquiring an additional 111 shares during the quarter. Johnson & Johnson accounts for 2.2% of Climber Capital SA’s investment portfolio, making the stock its 20th biggest holding. Climber Capital SA’s holdings in Johnson & Johnson were worth $366,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.1%

Shares of Johnson & Johnson stock opened at $152.33 on Thursday. The firm has a market cap of $366.52 billion, a PE ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a fifty day moving average price of $153.95 and a 200-day moving average price of $153.67.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.41%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is 57.84%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JNJ shares. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays lowered their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Bank of America dropped their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Finally, Raymond James Financial decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.